GTHX Annual CFO
-$38.34 M
+$90.28 M+70.19%
31 December 2023
Summary:
As of January 21, 2025, GTHX annual cash flow from operations is -$38.34 million, with the most recent change of +$90.28 million (+70.19%) on December 31, 2023. During the last 3 years, it has risen by +$45.41 million (+54.22%).GTHX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTHX Quarterly CFO
-$5.27 M
+$3.62 M+40.73%
30 June 2024
Summary:
As of January 21, 2025, GTHX quarterly cash flow from operations is -$5.27 million, with the most recent change of +$3.62 million (+40.73%) on June 30, 2024. Over the past year, it has dropped by -$19.36 million (-137.44%).GTHX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTHX TTM CFO
-$37.54 M
-$19.36 M-106.47%
30 June 2024
Summary:
As of January 21, 2025, GTHX TTM cash flow from operations is -$37.54 million, with the most recent change of -$19.36 million (-106.47%) on June 30, 2024. Over the past year, it has increased by +$29.31 million (+43.84%).GTHX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GTHX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +70.2% | -137.4% | +43.8% |
| 3 y3 years | +54.2% | -137.4% | +43.8% |
| 5 y5 years | +48.4% | +77.0% | +66.2% |
GTHX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +176.9% | -137.4% | +609.5% |
G1 Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$5.27 M(-40.7%) | -$37.54 M(+106.5%) |
| Mar 2024 | - | -$8.90 M(-30.4%) | -$18.18 M(-52.6%) |
| Dec 2023 | -$38.34 M(-70.2%) | -$12.79 M(+20.9%) | -$38.34 M(-31.8%) |
| Sept 2023 | - | -$10.58 M(-175.1%) | -$56.18 M(-16.0%) |
| June 2023 | - | $14.09 M(-148.5%) | -$66.85 M(-44.1%) |
| Mar 2023 | - | -$29.05 M(-5.2%) | -$119.49 M(-7.1%) |
| Dec 2022 | -$128.62 M(-2.6%) | -$30.63 M(+44.2%) | -$128.62 M(-3.0%) |
| Sept 2022 | - | -$21.25 M(-44.9%) | -$132.65 M(-8.8%) |
| June 2022 | - | -$38.56 M(+1.0%) | -$145.48 M(+1.4%) |
| Mar 2022 | - | -$38.18 M(+10.2%) | -$143.41 M(+8.6%) |
| Dec 2021 | -$132.11 M(+57.8%) | -$34.66 M(+1.7%) | -$132.11 M(+2.4%) |
| Sept 2021 | - | -$34.08 M(-6.6%) | -$128.96 M(+41.3%) |
| June 2021 | - | -$36.49 M(+35.7%) | -$91.24 M(+9.1%) |
| Mar 2021 | - | -$26.88 M(-14.7%) | -$83.60 M(-0.2%) |
| Dec 2020 | -$83.74 M | -$31.51 M(-965.8%) | -$83.74 M(+1.8%) |
| Sept 2020 | - | $3.64 M(-112.6%) | -$82.25 M(-25.9%) |
| June 2020 | - | -$28.85 M(+6.7%) | -$111.01 M(+5.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$27.02 M(-9.9%) | -$105.05 M(+5.5%) |
| Dec 2019 | -$99.57 M(+34.0%) | -$30.01 M(+19.4%) | -$99.57 M(+9.7%) |
| Sept 2019 | - | -$25.13 M(+9.8%) | -$90.79 M(+10.1%) |
| June 2019 | - | -$22.89 M(+6.2%) | -$82.47 M(+6.1%) |
| Mar 2019 | - | -$21.55 M(+1.5%) | -$77.74 M(+4.6%) |
| Dec 2018 | -$74.31 M(+47.1%) | -$21.23 M(+26.3%) | -$74.31 M(+9.6%) |
| Sept 2018 | - | -$16.81 M(-7.4%) | -$67.83 M(+4.7%) |
| June 2018 | - | -$18.16 M(+0.3%) | -$64.77 M(+9.1%) |
| Mar 2018 | - | -$18.11 M(+22.8%) | -$59.35 M(+17.5%) |
| Dec 2017 | -$50.52 M(+100.9%) | -$14.75 M(+7.2%) | -$50.52 M(+12.3%) |
| Sept 2017 | - | -$13.76 M(+8.0%) | -$44.98 M(+23.2%) |
| June 2017 | - | -$12.74 M(+37.3%) | -$36.51 M(+25.3%) |
| Mar 2017 | - | -$9.28 M(+0.8%) | -$29.13 M(+15.9%) |
| Dec 2016 | -$25.14 M(+81.6%) | -$9.21 M(+74.3%) | -$25.14 M(+57.8%) |
| Sept 2016 | - | -$5.29 M(-1.3%) | -$15.93 M(+49.6%) |
| June 2016 | - | -$5.35 M(+1.2%) | -$10.65 M(+101.2%) |
| Mar 2016 | - | -$5.29 M | -$5.29 M |
| Dec 2015 | -$13.85 M | - | - |
FAQ
- What is G1 Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for G1 Therapeutics?
- What is G1 Therapeutics annual CFO year-on-year change?
- What is G1 Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for G1 Therapeutics?
- What is G1 Therapeutics quarterly CFO year-on-year change?
- What is G1 Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for G1 Therapeutics?
- What is G1 Therapeutics TTM CFO year-on-year change?
What is G1 Therapeutics annual cash flow from operations?
The current annual CFO of GTHX is -$38.34 M
What is the all time high annual CFO for G1 Therapeutics?
G1 Therapeutics all-time high annual cash flow from operations is -$13.85 M
What is G1 Therapeutics annual CFO year-on-year change?
Over the past year, GTHX annual cash flow from operations has changed by +$90.28 M (+70.19%)
What is G1 Therapeutics quarterly cash flow from operations?
The current quarterly CFO of GTHX is -$5.27 M
What is the all time high quarterly CFO for G1 Therapeutics?
G1 Therapeutics all-time high quarterly cash flow from operations is $14.09 M
What is G1 Therapeutics quarterly CFO year-on-year change?
Over the past year, GTHX quarterly cash flow from operations has changed by -$19.36 M (-137.44%)
What is G1 Therapeutics TTM cash flow from operations?
The current TTM CFO of GTHX is -$37.54 M
What is the all time high TTM CFO for G1 Therapeutics?
G1 Therapeutics all-time high TTM cash flow from operations is -$5.29 M
What is G1 Therapeutics TTM CFO year-on-year change?
Over the past year, GTHX TTM cash flow from operations has changed by +$29.31 M (+43.84%)